BLOOD SYSTEM UNDER COVID-19 INFECTION: PATHOGENIC MECHANISMS OF DISORDERS AND PERSPECTIVES OF THERAPY

DOI: https://doi.org/10.29296/24999490-2020-05-01

A.K. Martusevich Privozhsky Research Medical University, Minin sq., 10/1, Nizhny Novgorod, 603950, Russian Federation E-mail: [email protected]

The purpose of this review is a systematic analysis of data from clinical observations, international experience, and reviews related to the pathogenetic aspects of the impact of a new coronavirus infection on the blood system. Information was searched in MedLine, PubMed, and RSCI databases. A brief description of the etiological agent with a detailed analysis of the structure of this virus is given. The features and mechanisms of immunological shifts induced by SARS-CoV-2 infection are analyzed. Hematological and metabolic changes in the blood of COVID-19 patients are presented and described. The reaction of erythron to the development of a new coronavirus infection was evaluated from pathogenetic and clinical positions. In whole, the agent of a new coronavirus infection was shown in patients to have a multifaceted negative effect on the blood system, which is reflected in the dysfunction of the immune system (predominantly cellular) with the formation of a special syndrome termed as «cytokine storm», a hypercoagulable state until the development of disseminated intravascular coagulation, as well as reducing the absolute number of all formed elements of blood. Understanding the mechanisms of development of these shifts creates opportunities for delivering new technologies for targeted therapy.
Keywords: 
SARS-CoV-2, COVID-19, pathogenesis, pathogenic therapy, review
Список литературы: 
  1. Martusevich A.K., Peretjagin S.P. Novaja koronavirusnaja infektsija (COVID-19) kak global'naja ugroza chelovechestvu: nekotorye voprosy epidemiologii, patogeneza i diagnostiki. Bioradikaly i antioksidanty. 2020; 7 (1): 42–71. [Martusevich A.K., Peretyagin S.P. New coronavirus infection (COVID-19) as a global challenge to humanity: some aspects of epidemiology, pathogenesis and diagnostics. Bioradikaly i antioxidanty. 2020; 7 (1): 42–71 (in Russian)]
  2. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395: 565.
  3. McIntosh K. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, clinical features, diagnosis, and prevention. https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-epidemiology-virology-clinical-features-diagnosis-and-prevention
  4. Perlman S. Another Decade, Another Coronavirus. N. Engl. J. Med. 2020; 382: 760.
  5. World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
  6. Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T. et al. Qin Ning Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019. J. Clin. Invest. 2020; 130 (5): 2620–9. https://doi.org/10.1172/JCI137244.
  7. Frater J.L., Zini G., d’Onofrio G., Rogers H.J. COVID-19 and the Clinical Hematology Laboratory. Int. J. Lab. Hematol. 2020. https://doi.org/10.1111/ijlh.13229. Online ahead of print.
  8. Wang F., Hou H., Luo Y., Tang G., Wu S., Huang M., Liu W., Zhu Y., Lin Q., Mao L., Fang M., Zhang H., Sun Z. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020; 5 (10): e137799. https://doi.org/10.1172/jci.insight.137799.
  9. Gorenkov D.V., Hantimirova L.M., Shevtsov V.A., Rukavishnikov A.V., Merkulov V.A., Olefir Ju.V. Vspyshka novogo infektsionnogo zabolevanija COVID-19: β-koronavirusy kak ugroza global'nomu zdravoohraneniju. BIOpreparaty. Profilaktika, diagnostika, lechenie. 2020; 20 (1): 6–20. https://doi.org/10.30895/2221-996X-2020-20-1-6-20 [Gorenkov D.V., Khantimirova L.M., Shevtsov V.A., Rukavishnikov A.V., Merkulov V.A., Olefir Yu.V. Outbreak of a new infectious disease COVID-19: β-coronaviruses as a threat to global health. biologicals. Prevention, diagnosis, and treatment. 2020; 20 (1): 6–20 https://doi.org/10.30895/2221-996X-2020-20-1-6-20 (in Russian)]
  10. L'vov D.K., Al'hovskij S.V., Kolobuhina L.V., Burtseva E.I. Etiologija epidemicheskoj vspyshki COVID-19 v g. Uhan' (provintsija Hubej, Kitajskaja Narodnaja Respublika), assotsiirovannoj s virusom 2019-CoV (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, podrod Sarbecovirus): uroki epidemii SARS-CoV. Voprosy virusologii. 2020; 65 (1): 6–15. https://doi.org/10.36233/0507-4088-2020-65-1–6-15 [Lvov D.K., Alkhovsky S.V., Kolobukhina L.V., Burtseva E.I. Etiology of the COVID-19 epidemic outbreak in Wuhan (Hubei province, people’s Republic of China) associated with the 2019-CoV virus (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, subgenus Sarbecovirus): lessons from the SARS-CoV epidemic. Questions of Virology. 2020; 65 (1): 6–15 https://doi.org/10.36233/0507-4088-2020-65-1–6-15 (in Russian)]
  11. Nikiforov V.V., Suranova T.G., Chernobrovkina T.Ja., Jankovskaja Ja.D., Burova S.V. Novaja ko- ronavirusnaja infektsija (covid-19): kliniko- epidemiologicheskie aspekty. Arhiv' vnut- rennej meditsiny. 2020; 10 (2): 87–93. https://doi.org/10.20514/2226-6704-2020-10-2-87-93 [Nikiforov V.V., Suranova T.G., Chernobrovkina T.Ya., Yankovskaya Ya.D., Burova S.V. New coronavirus infection (covid-19): clinical and epidemiological aspects. Arhivʺ vnutrennej mediciny. 2020; 10 (2): 87–93. https://doi.org/10.20514/2226-6704-2020-10-2-87-93 (in Russian)]
  12. Starshinova A.A., Kushnareva E.A., Malkova A.M., Dovgaljuk I.F., Kudlaj D.A. Novaja koronavirusnaja infektsija: osobennosti klinicheskogo techenija, vozmozhnosti diagnostiki, lechenija i profilaktiki infektsii u vzroslyh i detej. Voprosy sovremennoj pediatrii. 2020; 19(2): 123-131.
  13. Abaturov A.E., Agafonova E.A., Krivusha E.L., Nikulina A.A. Patogenez COVID-19. Zdorov'e rebenka. 2020; 15 (2): 133–44. https://doi.org/10.22141/2224-0551.15.1.2020.200598 [Abaturov A.E., Agafonova E.A., Krivusha E.L., Nikulina A.A. Pathogenesis of COVID-19. Zdorov’e Rebenka. 2020; 15 (2): 133–44. https://doi.org/10.22141/2224-0551.15.1.2020.200598 (in Russian)]
  14. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270.
  15. Gorbalenya A.E., Baker S.C., Baric R.S., de Groot R.J., Drosten C., Gulyaeva A.A., Haagmans B.L., Lauber C., Leontovich A.M., Neuman B.W. et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. bioRxiv 2020. https://www.biorxiv.org/content/10.1101/2020.02.07.937862v1
  16. Coleman C.M., Sisk J.M., Mingo R.M., Nelson E.A., White J.M., Frieman M.B. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J. Virol. 2016; 90 (19): 8924–33. https://doi.org/10.1128/JVI.01429-16.
  17. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020; 382: 727.
  18. Tang X., Wu C., Li X. et al. On the origin and continuing evolution of SARS-CoV-2. National Science Review 2020.
  19. Chaw S.-M., Tai J.-H., Chen S.-L., Hsieh C.-H., Chang S.-Y., Yeh S.-H., Yang W.-S., Chen P.-J., Wang H.-Y. The origin and underlying driving forces of the SARS-CoV-2 outbreak. J. Biomed. Sci. 2020; 27: 73. https://doi.org/10.1186/s12929-020-00665-8
  20. Li G., Fa Y., Lai Y., Han T., Li Z., Zhou P., Pan P., Wang W., Hu D., Liu X., Zhang Q., Wu J. Coronavirus Infections and Immune Responses. J. Med. Virol. 2020; 92 (4): 424–32. https://doi.org/10.1002/jmv.25685.
  21. Zhu F.-C., Li Y.-H., Guan X.-H., Hou L.-H., Wang W.-J., Li J.-X., Wu S.-P., Wang B.-S., Wang Z., Wang L., Jia S.-Y. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020. https://doi.org/10.1016/S0140-6736(20)31208-3
  22. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006; 124 (4): 783–801.
  23. Kell A.M., Gale M. Jr. RIG-I in RNA virus recognition. Virology. 2015; 479–480: 110–121.
  24. Yoneyama M., Fujita T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev. 2009; 227 (1): 54–65.
  25. Davis B.K., Roberts R.A., Huang M.T., Willingham S.B., Conti B.J., Brickey W.J., Barker B.R., Kwan M., Taxman D.J., Accavitti-Loper M.-A., Duncan J.A., Ting J. P.-Y. Cutting edge: NLRC5-dependent activation of the inflammasome. J. Immunol. 2011; 186 (3): 1333–7.
  26. Hornung V., Ablasser A., Charrel-Dennis M., Bauernfeind F., Horvath G., Caffrey D.R., Latz E., Fitzgerald K.A. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009; 458 (7237): 514–8.
  27. Inohara C., McDonald C., Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu. Rev. Biochem. 2005; 74: 355–83.
  28. Zhu X., Wang Y., Zhang H., Liu X., Chen T., Yang R., Shi Y., Cao W., Li P., Ma Q., Zhai Y., He F., Zhou G., Cao C. Genetic variation of the human alpha-2-Heremans-Schmid glycoprotein (AHSG) gene associated with the risk of SARS-CoV infection. PLOS One. 2011; 6 (8): e23730.
  29. Shanmugaraj B., Siriwattananon K., Wangkanont K., Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac. J. Allergy Immunol. 2020; 38: 10–8. https://doi.org/10.12932/AP-200220-0773
  30. Ye Q., Wang B., Mao J. The pathogenesis and treatment of the «Cytokine Storm» in COVID-19. J. Infect. 2020; 80 (6): 607–13. https://doi.org/10.1016/j.jinf.2020.03.037.
  31. Ulrich H., Pillat M.M. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. Stem Cell Reviews and Reports. 2020; 16: 434–40.
  32. Lippi G., Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020. https://doi.org/10.1515/cclm-2020-0198.
  33. Giannis D., Ziogas I.A., Gianni P. Coagulation Disorders in Coronavirus Infected Patients: COVID-19, SARS-CoV-1, MERS-CoV and Lessons From the Past. J. Clin. Virol. 2020; 127: 104362. https://doi.org/10.1016/j.jcv.2020.104362.
  34. Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., Der Nigoghossian C., Ageno W., Madjid M., Guo Y. et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J. Am. Coll. Cardiol. 2020; S0735–1097 (20) 35008–7. https://doi.org/10.1016/j.jacc.2020.04.031.
  35. Bikdeli B., Madhavan M.V., Gupta A., Jimenez D., Burton J.R., Der Nigoghossian C. et al. (Global COVID-19 Thrombosis Collaborative Group) Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb. Haemost. 2020. https://doi.org/10.1055/s-0040-1713152.
  36. Bohm M., Frey N., Giannitsis E., Sliwa K., Zeiher A.M. Coronavirus Disease 2019 (COVID-19) and Its Implications for Cardiovascular Care: Expert Document From the German Cardiac Society and the World Heart Federation. Clin. Res. Cardiol. 2020; 1–14. https://doi.org/10.1007/s00392-020-01656-3.
  37. Vivas D., Roldán V., Esteve-Pastor M.A., Roldán I., Tello-Montoliu A., Ruiz-Nodar J.M., Cosin-Sales J., Gámez J.M., Consuegra L., Ferreiro J.L., Marin F., Arrarte V., Anguita M., Cequier Á., Pérez-Villacastin J. Recommendations on Antithrombotic Treatment During the COVID-19 Pandemic. Position Statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. Rev. Esp. Cardiol . 2020. https://doi.org/10.1016/j.recesp.2020.04.006.
  38. Watson R.A., Johnson D.M., Dharia R.N., Merli G.J., Doherty J.U. Anti-Coagulant and Anti-Platelet Therapy in the COVID-19 Patient: A Best Practices Quality Initiative Across a Large Health System. Hosp. Pract. 2020. https://doi.org/10.1080/21548331.2020.1772639.
  39. Lorenzo C., Francesca B., Francesco P., Elena C., Luca S., Paolo S. Acute Pulmonary Embolism in COVID-19 Related Hypercoagulability. J. Thromb. Thrombolysis. 2020; 1–4. https://doi.org/10.1007/s11239-020-02160-1.
  40. Emert R., Shah P., Zampella J.G. COVID-19 and Hypercoagulability in the Outpatient Setting. Thromb. Res. 2020; 192: 122–3. https://doi.org/10.1016/j.thromres.2020.05.031.
  41. Spyropoulos A.C., Ageno W., Barnathan E.S. Hospital-based Use of Thromboprophylaxis in Patients With COVID-19. Lancet. 2020; 395 (10234): e75. https://doi.org/10.1016/S0140-6736(20)30926-0.
  42. Mei H., Hu Y. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19. Zhonghua Xue Ye Xue Za Zhi. 2020; 41 (3): 185–91. https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0002.
  43. Zhang Y., Cao W., Xiao M., Li Y.J., Yang Y., Zhao J. et al. Clinical and Coagulation Characteristics of 7 Patients With Critical COVID-2019 Pneumonia and Acro-Ischemia. Zhonghua Xue Ye Xue Za Zhi. 2020; 41 (0): E006. https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0006.
  44. Thachil J. The Versatile Heparin in COVID-19. J. Thromb. Haemost. 2020; 18 (5): 1020–2. https://doi.org/10.1111/jth.14821.
  45. Zhang Y., Xiao M., Zhang S., Xia P., Cao W., Jiang W., Chen H., Ding X., Zhao H., Zhang H. et al. Coagulopathy and Antiphospholipid Antibodies in Patients With Covid-19. N. Engl. J. Med. 2020; 382 (17): e38. https://doi.org/10.1056/NEJMc2007575.
  46. Gavillet M., Rufer N., Grandoni F., Klappert J.C., Zermatten M.G., Cairoli A., Canellini G., Alberio L., Duchosal M.A., Spertini O., Blum S. Hematology in the Time of COVID-19. Rev. Med. Suisse. 2020; 16 (691–2): 823–6.
  47. Lippi G., Plebani M., Henry B.M. Thrombocytopenia Is Associated With Severe Coronavirus Disease 2019 (COVID-19) Infections: A Meta-Analysis. Clin. Chim. Acta. 2020; 506: 145–8. https://doi.org/10.1016/j.cca.2020.03.022.
  48. Tan L., Wang Q., Zhang D., Ding J., Huang Q., Tang Y.-Q., Wang Q., Miao H. Lymphopenia Predicts Disease Severity of COVID-19: A Descriptive and Predictive Study. Signal Transduct. Target. Ther. 2020; 5 (1): 33. https://doi.org/10.1038/s41392-020-0148-4.
  49. Lippi G., Plebani M. Procalcitonin in Patients With Severe Coronavirus Disease 2019 (COVID-19): A Meta-Analysis. Clin. Chim. Acta. 2020; 505: 190–1. https://doi.org/10.1016/j.cca.2020.03.004.
  50. Ji H.-L., Zhao R., Matalon S., Matthay M.A. Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. Physiol. Rev. 2020; 100 (3): 1065–75. https://doi.org/10.1152/physrev.00013.2020.
  51. Barnes B.J., Adrover J.M., Baxter-Stoltzfus A., Borczuk A., Cools-Lartigue J., Crawford J.M., Daßler-Plenker J., Guerci P., Huynh C., Knight J.S. et al. Targeting Potential Drivers of COVID-19: Neutrophil Extracellular Traps. J. Exp. Med. 2020; 217 (6): e20200652. https://doi.org/10.1084/jem.20200652.
  52. Lu G., Wang J. Dynamic Changes in Routine Blood Parameters of a Severe COVID-19 Case. Clin Chim Acta. 2020; 508: 98–102. https://doi.org/10.1016/j.cca.2020.04.034.
  53. Luo Y., Yuan X., Xue Y., Mao L., Lin Q., Tang G., Song H., Liu W., Hou H., Wang F., Sun Z. Using a Diagnostic Model Based on Routine Laboratory Tests to Distinguish Patients Infected With SARS-CoV-2 From Those Infected With Influenza Virus. Int. J. Infect. Dis. 2020; 95: 436–40. https://doi.org/10.1016/j.ijid.2020.04.078.
  54. Lapić I., Rogić D., Plebani M. Erythrocyte Sedimentation Rate Is Associated With Severe Coronavirus Disease 2019 (COVID-19): A Pooled Analysis. Clin. Chem. Lab. Med. 2020. https://doi.org/10.1515/cclm-2020-0620.
  55. Wang Z., Du Z., Zhu F. Glycosylated Hemoglobin Is Associated With Systemic Inflammation, Hypercoagulability, and Prognosis of COVID-19 Patients. Diabetes Res Clin Pract. 2020; 164: 108214. https://doi.org/10.1016/j.diabres.2020.108214.
  56. Lehene M., Fischer-Fodor E., Scurtu F., Hadade N.D., Gal E., Mot A.C., Matei A., Silaghi-Dumitrescu R. Excess ascorbate is a chemical stress agent against proteins and cells. Pharmaceuticals (Basel). 2020; 13 (6): E107. https://doi.org/10.3390/ph13060107.